Introduction Treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC) include androgen deprivation therapy (ADT) plus docetaxel chemotherapy or a second-generation hormonal agent with uncertainty about which treatment option should be used in this setting. I propose a differential treatment response between ADT and docetaxel and ADT and abiraterone acetate and prednisolone (AAP) based on nodal metastases. Also, increased metastatic disease burden is associated with worse survival outcomes but nodal metastases have not yet been considered in risk stratification for this cohort. Methods Nodal burden was dichotomized into low (
Date of Award | 31 Dec 2023 |
---|
Original language | English |
---|
Awarding Institution | - The University of Manchester
|
---|
Supervisor | Michael Brown (Supervisor), Noel Clarke (Supervisor) & Ashwin Sachdeva (Supervisor) |
---|
Correlating imaging with disease outcome in metastatic hormone-sensitive prostate cancer- the STAMPEDE analysis
Haran, A. (Author). 31 Dec 2023
Student thesis: Phd